Table 2.

Risk factors of post-ERCP pancreatitis

	Pancreatitis (+) (n = 47)	Pancreatitis (-) (n = 1244)	P
Male:female	31:16	707:537	0.21
Pancreatic duct opacification	37 (78%)	838 (67%)	0.10
Difficult bile duct cannulation	7 (14%)	100 (8%)	0.09
Intraductal ultrasonography	13 (28%)	253 (20%)	0.22
Biliary sphincterotomy	12 (26%)	258 (20%)	0.42
Biliary stent placement	10 (21%)	150 (12%)	0.06
Biliary stent placement without sphx1	5 (10%)	42 (3%)	0.026
Papillary balloon dilatation	4 (8%)	46 (4%)	0.20
Cytology of the bile/pancreatic juice	4 (8%)	49 (3.9%)	0.12
Biopsy of the bile/pancreatic duct	2 (4%)	76 (6%)	0.60
Gallbladder stone	15 (32%)	433 (34%)	0.68
Choledocholithiasis	15 (32%)	298 (24%)	0.21
Cholangiocarcinoma	5 (10%)	70 (6%)	0.14
Pancreatic cancer	3 (6%)	70 (6%)	0.92
Intraductal papillary mucinous neoplasm	5 (10%)	58 (4%)	0.12
Ampullary cancer	0	23 (2%)	0.70
Pancreaticobiliary maljunction	0	20 (2%)	0.78

¹Sphx: sphincterotomy.